The global Biological Products Safety Testing Service market size is predicted to grow from US$ 4400 million in 2025 to US$ 8750 million in 2031; it is expected to grow at a CAGR of 12.1% from 2025 to 2031.
Biosafety testing is a series of assays to evaluate the potential biological risks of new biological products, including viral testing, microbial testing, cell and molecular testing, and analytic testing. Health authorities such as the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) require all biopharmaceutical products and vaccines to undergo stringent testing to ensure the product is safe and free of contaminants.
- Key Features:
This Insight Report provides a comprehensive analysis of the global Biological Products Safety Testing Service landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity.
Segmentation by Type:
- Raw Materials
- Viral Banks
- Cell Banks
- Others
Segmentation by Application:
- Pharmaceutical and Biotechnology Companies
- CROs and CDMOs
- Academic and Research Institutions
Market by Region:
- Americas
- APAC
- Europe
- Middle East & Africa
Companies Coverage:
- Merck
- Charles River Laboratories
- Sartorius
- Eurofins Scientific
- SGS
- Q2 Solutions
- Samsung Biologics
- Texcell
- WuXi Biologics
- Wuhan Canvest Biotechnology
- Centre Testing International (CTI)
- Suzhou Liangchen Biotechnology
- JADE Biomedical
- Standard Testing Group
- Sino Tech World Biologicals
- CAS Testing Technical Services
- NTEK
- Sino Biological
- Miracle Points
- Suzhou Cefety Bioscience
- Zhejiang Hengyu Biological
Key Questions Addressed in this Report:
Frequently Asked Questions
What is the USP of the report? expand_more
What are the key content of the report? expand_more
- Global Market Players
- Geopolitical regions
- Consumer Insights
- Technological advancement
- Historic and Future Analysis of the Market